Previous 10 | Next 10 |
SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is please...
SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is please...
SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited...
Nascent Biotech ([[NBIO]] +19.2%) announces the publication of In-Vitro study results from its research collaboration with Syracuse University, with data arising from this research suggesting that its Pritumumab antibody blocks uptake of COVID-19, reducing the spread of the infection in ...
SAN DIEGO, CA / ACCESSWIRE / February 17, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"), a clinical-stage biotech company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce t...
SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") is pleased to announce that the Company has received initial In-Vitro study results from its collaboration with Syracuse University showing that Pritumumab ("PTB") successf...
SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials t...
SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts payable and accrued liabilities. The reduction was achieved through the conversion of debt to equ...
SAN DIEGO, CA / ACCESSWIRE / August 24, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000. The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold...
SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has significantly reduced its liabilities through stock conversion and payment of accrued liabilities. The reduction was achieved through the conversion of $1,600,000 in debt to equity a...
News, Short Squeeze, Breakout and More Instantly...
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturin...
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray ® "), a clinical...
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announc...